propose

# Novel Therapeutic Hypotheses for Perivascular Spaces and Glymphatic Clearance in AD

## 1. Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation

**Description:** Chronic activation of TREK-1 potassium channels in astrocytic endfeet could restore AQP4 polarization by modulating membrane lipid composition and cytoskeletal organization. TREK-1 activation increases membrane fluidity and promotes proper localization of dystrophin-associated protein complexes that anchor AQP4.

**Target:** KCNK2 (TREK-1 channel)

**Supporting Evidence:** AQP4 mislocalization is a hallmark of AD glymphatic dysfunction (PMID: 25904740). TREK-1 channels regulate astrocyte volume and membrane properties (PMID: 28515314). Mechanical forces transmitted through TREK-1 influence cytoskeletal organization in astrocytes.

**Confidence:** 0.75

## 2. Pericyte Contractility Reset via Selective PDGFR-β Agonism

**Description:** Designer PDGFR-β agonists with biased signaling toward contractility pathways (avoiding proliferative signals) could restore pericyte tone and perivascular space dimensions. This would target the PI3K/Akt pathway while avoiding MAPK activation to prevent pathological proliferation.

**Target:** PDGFRB (selective pathway activation)

**Supporting Evidence:** Pericyte dysfunction and loss correlate with enlarged perivascular spaces in AD (PMID: 29146904). PDGFR-β signaling regulates pericyte contractility and BBB integrity (PMID: 25762414). Selective pathway modulation is achievable with biased agonists.

**Confidence:** 0.68

## 3. Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation

**Description:** Dual orexin receptor antagonists administered in precise circadian timing could enhance sleep-dependent glymphatic clearance by increasing norepinephrine withdrawal duration and depth. This would extend the critical slow-wave sleep phases when glymphatic flow peaks.

**Target:** HCRTR1/HCRTR2 (orexin receptors)

**Supporting Evidence:** Glymphatic clearance is dramatically enhanced during sleep via norepinephrine reduction (PMID: 24136970). Orexin neurons regulate sleep-wake transitions and norepinephrine release (PMID: 28659169). AD patients show disrupted sleep architecture and reduced glymphatic function.

**Confidence:** 0.82

## 4. Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition

**Description:** Selective inhibition of lysyl oxidase (LOX) enzymes could reduce pathological collagen cross-linking in perivascular spaces, restoring tissue compliance necessary for effective CSF-ISF exchange. This targets the mechanical properties of the extracellular matrix surrounding vessels.

**Target:** LOX/LOXL1-4 family

**Supporting Evidence:** Brain stiffness increases with aging and AD progression (PMID: 31578193). Lysyl oxidase activity correlates with tissue fibrosis and stiffness (PMID: 25190814). Perivascular fibrosis impedes glymphatic flow in neurodegeneration models.

**Confidence:** 0.71

## 5. Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation

**Description:** Targeted upregulation of syndecan-1 through small molecule enhancers or gene therapy could restore the endothelial glycocalyx layer, improving the hydrodynamic properties essential for paravascular CSF flow. This would enhance the "slip" conditions necessary for efficient glymphatic transport.

**Target:** SDC1 (syndecan-1)

**Supporting Evidence:** Glycocalyx degradation occurs in AD and impairs vascular function (PMID: 29367453). Syndecan-1 is a key structural component of the endothelial glycocalyx (PMID: 28442290). Intact glycocalyx is essential for proper fluid shear and paravascular flow dynamics.

**Confidence:** 0.79

## 6. Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation

**Description:** Selective inhibition of connexin-43 phosphorylation at serine residues (particularly Ser368) could maintain open gap junction channels between astrocytes, facilitating coordinated calcium waves that drive perivascular pumping. This would enhance the synchronized astroglial contractions necessary for glymphatic propulsion.

**Target:** GJA1 (connexin-43) and associated kinases (PKC, MAPK)

**Supporting Evidence:** Astrocyte calcium waves coordinate glymphatic clearance (PMID: 32457986). Connexin-43 phosphorylation regulates gap junction permeability (PMID: 20959514). AD brains show reduced astrocyte connectivity and gap junction function.

**Confidence:** 0.73

## 7. Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus

**Description:** Targeted upregulation of AQP1 specifically in choroid plexus epithelium could restore proper CSF production and osmotic driving forces for glymphatic flow. This would address the upstream deficit in CSF dynamics while avoiding systemic water handling effects.

**Target:** AQP1 (tissue-specific targeting)

**Supporting Evidence:** CSF production decreases with age and AD (PMID: 25078108). AQP1 is critical for CSF formation in choroid plexus (PMID: 15917345). Reduced CSF turnover impairs solute clearance and contributes to protein aggregation.

**Confidence:** 0.65